Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610554 | 1.00 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789749 | 0.82 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1880935 | 0.82 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14610584 | 0.82 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5109931 | 0.82 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789746 | 0.82 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10772086 | 0.81 | LMNA (0.67) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15723483 | 0.79 | LMNA (0.56) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12989970 | 0.75 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28977958 | 0.73 | LMNA (0.47) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2007021793-A1 | MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021793-A1 | MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | APP, BACE1, PSEN1 | LMNA 293/4885CA12 3429/4885CA1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.